LGL Group (NYSEAMERICAN:LGL) Posts Quarterly Earnings Results, Misses Estimates By $0.12 EPS

LGL Group (NYSEAMERICAN:LGL) announced its quarterly earnings data on Monday. The industrial products company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12), FiscalAI reports. The company had revenue of $0.68 million for the quarter, compared to analyst estimates of $0.50 million. LGL Group had a return on equity of 0.17% and a net margin of 1.66%.

LGL Group Stock Up 0.4%

LGL opened at $6.94 on Wednesday. LGL Group has a 12 month low of $5.45 and a 12 month high of $9.74. The company has a fifty day simple moving average of $7.13 and a 200 day simple moving average of $6.60. The stock has a market cap of $45.35 million, a P/E ratio of 694.19 and a beta of 0.31.

Analyst Ratings Changes

Separately, Zacks Research upgraded LGL Group to a “hold” rating in a report on Thursday, May 7th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock currently has an average rating of “Hold”.

Hedge Funds Weigh In On LGL Group

A hedge fund recently raised its stake in LGL Group stock. Osaic Holdings Inc. raised its stake in LGL Group, Inc. (The) (NYSEAMERICAN:LGL) by 15.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 20,250 shares of the industrial products company’s stock after buying an additional 2,710 shares during the period. Osaic Holdings Inc. owned about 0.38% of LGL Group worth $154,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 30.28% of the company’s stock.

LGL Group Company Profile

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.